3 security-"https:"-"https:"-"https:"-"https:" positions at Center for Biologics Evaluation and Research (CBER)

FDA Non-clinical Identification and Mitigation of Safety Risks During the Development and Licensure of Protein-therapeutics

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 16 hours ago

to understand the safety consequences of immune responses to neo-epitopes generated due to off-target gene editing. The following articles from our laboratory provide examples of research performed in our group

FDA Computational and Experimental Assessment of Engineered Biotherapeutics: Safety and Regulatory Considerations of Synonymous Gene Recoding

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 16 hours ago

Biol, 169718 (2026). https://doi.org:10.1016/j.jmb.2026.169718 Katneni, U.K., Liss, A., Holcomb, D., Katagiri, N., Hunt, R.C., Bar, H., Ismail, A., Komar, A.A. and Kimchi-Sarfaty, C.: Splicing

FDA Prophylactic Vaccine Against Visceral Leishmaniasis Post-doctoral Fellowship

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 16 hours ago

, and cellular and gene therapies. Research Project: The FDA laboratory has been conducting collaborative research on the evaluation of safety and efficacy characteristics of live attenuated Leishmania